跳至主要内容
临床试验/NCT00092365
NCT00092365已完成3 期

A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee

Merck Sharp & Dohme LLC0 个研究点目标入组 413 人开始时间: 2003年4月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
413
主要终点
Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.

研究概览

简要总结

The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.

详细描述

The duration of treatment is 6 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Osteoarthritis of the knee which requires treatment with medication for pain relief

排除标准

  • •Any known allergy to the study drugs

结局指标

主要结局

Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.

次要结局

  • OA of the knee as measured by PGART over 6 wks of treatment.
  • WOMAC Question #1 over 6 wks of treatment.

研究者

申办方类型
Industry
责任方
Sponsor

相似试验